Rivaroxaban treatment of cancer‐associated venous thromboembolism: Memorial Sloan Kettering Cancer Center institutional experience
| Autor: | Jeanette Batista, Michael E Singer, Krishna Juluru, Gerald A. Soff, Jodi V. Mones, Sean M. Devlin, Cy Wilkins, Jonathan Wills, Simon Mantha, Yimei Miao, Eva Haegler-Laube, Debra M. Sarasohn |
|---|---|
| Jazyk: | angličtina |
| Rok vydání: | 2019 |
| Předmět: |
medicine.medical_specialty
venous thromboembolism neoplasms 030204 cardiovascular system & hematology 03 medical and health sciences 0302 clinical medicine Internal medicine Medicine Cumulative incidence rivaroxaban Rivaroxaban lcsh:RC633-647.5 business.industry Genitourinary system Incidence (epidemiology) Cancer lcsh:Diseases of the blood and blood-forming organs Hematology Guideline medicine.disease Thrombosis 3. Good health Discontinuation aged 030220 oncology & carcinogenesis Original Article hemorrhage business Original Articles: Thrombosis medicine.drug |
| Zdroj: | Research and Practice in Thrombosis and Haemostasis Research and Practice in Thrombosis and Haemostasis, Vol 3, Iss 3, Pp 349-356 (2019) |
| ISSN: | 2475-0379 |
| Popis: | Background Low‐molecular‐weight heparin has been the preferred treatment of cancer‐associated thrombosis (CAT); however, emerging data support the use of direct oral anticoagulants (DOACs). Objectives The Memorial Sloan Kettering Cancer Center Clinical Pathway has served as the institutional guideline for the use of rivaroxaban to treat CAT since 2014. Key elements are to recommend against use of a DOAC in patients with active gastrointestinal (GI) or genitourinary tract lesions, and a prespecified dose reduction in the elderly (75+ years old). We present our institutional experience for treatment of CAT. Methods From January 2014 through September 2016, 1072 patients began rivaroxaban treatment for CAT; 91.9% had a solid tumor, 8.1% had hematologic malignancies, and 75% of patients with solid tumors had metastatic disease. All patients with CAT treated with rivaroxaban were included in this analysis, regardless of adherence to the Clinical Pathway. Results The 6‐month cumulative incidence of recurrent venous thromboembolism and major bleeding were 4.2% (95% confidence interval [CI], 2.7%‐5.7%) and 2.2% (95% CI, 1.1%‐3.2%), respectively. The incidence of clinically relevant non–major bleeding leading to discontinuation of rivaroxaban for at least 7 days was 5.5% (95% CI, 3.7%‐7.1%), and 73.3% of major bleeds occurred in the GI tract. The 6‐month cumulative mortality rate was 22.2% (95% CI, 19.4%‐24.9%). The elderly had similar rates of recurrent thrombosis and bleeding as those aged under 75 years. Conclusion Our institutional experience suggests that in appropriately selected patients, rivaroxaban may be used for treatment of CAT with promising safety and efficacy. |
| Databáze: | OpenAIRE |
| Externí odkaz: |
|
Plný text